|
|
| General |
| Study Status |
Progress Adequate |
| 522 Number / Requirement Number |
PS200008 / PSS001 |
| Date Original Plan Accepted |
04/30/2020
|
| Date Current Plan Accepted |
03/24/2022
|
| Study Name |
Postmarket Surveillance
|
| Device Name |
Control-iq technology
|
| Root Document Number |
K200467
|
| General Study Protocol Parameters |
| Study Design |
Prospective Cohort Study
|
| Data Source |
New Data Collection
|
| Comparison Group |
Historical Control
|
| Analysis Type |
Descriptive
|
| Study Population |
Adolescent: 13-18 yrs,
Transit. Adolescent A (distinctively) : 18-21 yrs,
Transit. Adolescent B (as adults) : 18-21 yrs,
Adult: >21
|
| Detailed Study Protocol Parameters |
| Study Objectives |
This postmarket surveillance study is a single-arm, prospective study. It is designed to assess 12-month safety in a real-world setting, and to
support the continued assessment of the Control-IQ System for the treatment of type 1 diabetes in the United States. In addition, data will be collected to assess glycemic outcomes and user experience.
|
| Study Population |
Children: 6-13 yrs, Adolescent: 13-18 yrs, Transit. Adolescent B (as adults): 18-21 yrs, Adult: >21
|
| Sample Size |
Overall sample size remains unchanged. Enrollment targets changed from 193 to 163 for the 6-9 years old cohort, and from 58 to 18, for the 6-13 years old cohort who are CGM naïve.
|
| Key Study Endpoints |
Safety Endpoints:
1. The composite rates of severe hypoglycemia (SH) and diabetic ketoacidosis (DKA), and
2. The safety of the automatic population of CGM readings the bolus calculator of the Control-IQ System
Secondary Endpoints:
3. To determine glycemic outcomes as a measure of efficacy of the Control-IQ System, and
4. To demonstrate patient-reported satisfaction with and trust in the Control-IQ System, usability of the system, and sleep quality.
|
| Follow-up Visits and Length of Follow-up |
Agree to provide HbA1c result,
obtained within the 6-month period prior to enrollment”. Participants will be considered screen failures if Control-IQ data has not been downloaded to t:connect 120 days after the baseline survey's completion.
|
| Interim or Final Data Summary |
| Interim Results |
There is a reduction in the reported rate of severe hypoglycemia events from 13.15 to 11.63 per 100 patient-years but an increase in diabetes ketoacidosis events from 1.02 to 1.42 per 100 patient-years for the current reporting period. There is no evidence that the auto-population of CGM values into the bolus calculator results in the calculation of insulin boluses that are less safe than boluses delivered not using the auto-population feature. There were no Unanticipated Adverse Device Effects.
|
| Actual Number of Patients Enrolled |
2726
|
| Actual Number of Sites Enrolled |
1
|
| Patient Followup Rate |
Total number of subjects reaching each designated study phase:
o 1-month survey: 1,868
o 2-month survey: 2114
o 3-month survey: 2185
o 4-month survey: 2240
o 5-month survey: 2216
o 6-month survey: 2161
o 7-month survey: 2103
o 8-month survey: 2,118
o 9-month survey: 2,103
o 10-month survey: 2,022
o 11-month survey: 1712
o 12-month survey: 1715
|
| Study Strengths and Weaknesses |
Strengths: Tandem has met their overall enrollment goals.
Weaknesses: The study population enrolled to date is predominantly White.
|
